Jacques Amar

List of Publications by Year
in descending order

41 papers	9,722 citations	218677 26 h-index	276875 41 g-index
46 all docs	46 docs citations	46 times ranked	12740 citing authors

#	Article	IF	Citations
1	Interactions between hypertension and inflammatory tone and the effect on blood pressure and outcomes in patients with COVIDâ€19. Journal of Clinical Hypertension, 2021, 23, 238-244.	2.0	5
2	Blood Microbiota Modification After Myocardial Infarction Depends Upon Lowâ€Density Lipoprotein Cholesterol Levels. Journal of the American Heart Association, 2019, 8, e011797.	3.7	27
3	Microbiotaâ€“Host Crosstalk: A Bridge Between Cardiovascular Risk Factors, Diet, and Cardiovascular Disease. American Journal of Hypertension, 2018, 31, 941-944.	2.0	10
4	Identification by highly sensitive 16S metagenomic sequencing of an unusual case of polymicrobial bacteremia. Journal of Infection, 2017, 75, 278-280.	3.3	11
5	Hypertension and pregnancy: expert consensus statement from the French Society of Hypertension, an affiliate of the French Society of Cardiology. Fundamental and Clinical Pharmacology, 2017, 31, 83-103.	1.9	30
6	Comprehensive description of blood microbiome from healthy donors assessed by 16<scp>S</scp> targeted metagenomic sequencing. Transfusion, 2016, 56, 1138-1147.	1.6	355
7	Triggering the adaptive immune system with commensal gut bacteria protects against insulin resistance and dysglycemia. Molecular Metabolism, 2016, 5, 392-403.	6.5	50
8	Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis. Hepatology, 2016, 64, 2015-2027.	7.3	230
9	Defective <scp>NOD</scp>2 peptidoglycan sensing promotes dietâ€induced inflammation, dysbiosis, and insulin resistance. EMBO Molecular Medicine, 2015, 7, 259-274.	6.9	160
10	The Characterization of Novel Tissue Microbiota Using an Optimized 16S Metagenomic Sequencing Pipeline. PLoS ONE, 2015, 10, e0142334.	2.5	155
11	Antibiotics or prodiabetics?. Nature Reviews Endocrinology, 2015, 11, 385-386.	9.6	5
12	The Gut Microbiota Regulates Intestinal CD4ÂT Cells Expressing RORÎ³t and Controls Metabolic Disease. Cell Metabolism, 2015, 22, 100-112.	16.2	248
13	Gut Microbiota and Metabolic Diseases: From Pathogenesis to Therapeutic Perspective. Molecular and Integrative Toxicology, 2015, , 199-234.	0.5	7
14	Metagenome and metabolism: the tissue microbiota hypothesis. Diabetes, Obesity and Metabolism, 2013, 15, 61-70.	4.4	112
15	Blood Microbiota Dysbiosis Is Associated with the Onset of Cardiovascular Events in a Large General Population: The D.E.S.I.R. Study. PLoS ONE, 2013, 8, e54461.	2.5	201
16	Metabolic adaptation to a high-fat diet is associated with a change in the gut microbiota. Gut, 2012, 61, 543-553.	12.1	511
17	Gut microbiota and diabetes: from pathogenesis to therapeutic perspective. Acta Diabetologica, 2011, 48, 257-273.	2.5	199
18	Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept. Diabetologia, 2011, 54, 3055-3061.	6.3	283

#	Article	IF	Citations
19	Prediction of persistence of combined evidence-based cardiovascular medications in patients with acute coronary syndrome after hospital discharge using neural networks. Medical and Biological Engineering and Computing, 2011, 49, 947-955.	2.8	17
20	Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Molecular Medicine, 2011, 3, 559-572.	6.9	694
21	The gut microbiota ecology: a new opportunity for the treatment of metabolic diseases ?. Frontiers in Bioscience - Landmark, 2009, 14, 5107.	3.0	52
22	Poor blood pressure control in general practice: In search of explanations. Archives of Cardiovascular Diseases, 2009, 102, 477-483.	1.6	15
23	Six-item self-administered questionnaires in the waiting room: an aid to explain uncontrolled hypertension in high-risk patients seen in general practice. Journal of the American Society of Hypertension, 2009, 3, 221-227.	2.3	18
24	Persistence of combination of evidence-based medical therapy in patients with acute coronary syndromes. Archives of Cardiovascular Diseases, 2008, 101, 301-306.	1.6	16
25	Energy intake is associated with endotoxemia in apparently healthy men. American Journal of Clinical Nutrition, 2008, 87, 1219-1223.	4.7	498
26	Patients with resistant hypertension. Journal of Hypertension, 2007, 25, S3-S6.	0.5	9
27	Metabolic Endotoxemia Initiates Obesity and Insulin Resistance. Diabetes, 2007, 56, 1761-1772.	0.6	4,964
28	Interleukin 6 is associated with subclinical atherosclerosis: a link with soluble intercellular adhesion molecule 1. Journal of Hypertension, 2006, 24, 1083-1088.	0.5	64
29	Baseline and target blood pressure for the prevention of recurrent stroke. Journal of Hypertension, 2006, 24, 2473.	0.5	0
30	Arteries, inflammation and insulin resistance. Journal of Hypertension, 2006, 24, S18-S20.	0.5	11
31	Cardiovascular Risk Factors, Atherosclerosis and Pulse Pressure. , 2006, 44, 212-222.		14
32	C-Reactive Protein Elevation Predicts Pulse Pressure Reduction in Hypertensive Subjects. Hypertension, 2005, 46, 151-155.	2.7	33
33	Comparison of Hypertension Management After Stroke and Myocardial Infarction. Stroke, 2004, 35, 1579-1583.	2.0	28
34	Commentary. Evidence-based Cardiovascular Medicine, 2004, 8, 32-33.	0.0	0
35	CD14 C(â^'260)T gene polymorphism, circulating soluble CD14 levels and arteriosclerosis. Journal of Hypertension, 2004, 22, 1523-1528.	0.5	24
36	Relationship between C reactive protein and pulse pressure is not mediated by atherosclerosis or aortic stiffness. Journal of Hypertension, 2004, 22, 349-355.	0.5	34

#	Article	IF	Citations
37	Why is hypertension so frequently uncontrolled in secondary prevention?. Journal of Hypertension, 2003, 21, 1199-1205.	0.5	53
38	Soluble CD14 and aortic stiffness in a population-based study. Journal of Hypertension, 2003, 21, 1869-1877.	0.5	54
39	Hypertension in high-risk patients: beware of the underuse of effective combination therapy (results) Tj ETQq1 1 0.784314 rgBT /Over	0.5	56
40	Arterial stiffness and cardiovascular risk factors in a population-based study. Journal of Hypertension, 2001, 19, 381-387.	0.5	242
41	Nocturnal blood pressure and 24-hour pulse pressure are potent indicators of mortality in hemodialysis patients. Kidney International, 2000, 57, 2485-2491.	5.2	211